Based on early-stage clinical trials results so far, Genentech said it will take its oral GLP-1 drug, part of its $3 billion acquisition of Carmot Therapeutics, into a mid-stage clinical trial.
Ron Leuty
Source link
Big Portland biotech employer gets obesity drug boost
